Cyteir Therapeutics Inc - ESG Rating & Company Profile powered by AI
Scroll down to the bottom of the page for potential risks for Cyteir Therapeutics Inc based on sector, geography and marketcap. If you work at Cyteir Therapeutics Inc and you wish to licence your ESG aseessment, please get in touch. This page includes a questions and answers table on Cyteir Therapeutics Inc.
Cyteir Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 4.0, social score of 3.2 and governance score of 3.2.
3.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1144 | Veerhealth Care Ltd | 3.6 | Medium |
| 1144 | iStreet Network Ltd | 3.6 | Medium |
| 1186 | Cyteir Therapeutics Inc | 3.5 | Medium |
| 1186 | CRISPR Therapeutics AG | 3.5 | Medium |
| 1186 | Catalent Inc | 3.5 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Cyteir Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Cyteir Therapeutics Inc disclose current and historical energy intensity?
Does Cyteir Therapeutics Inc report the average age of the workforce?
Does Cyteir Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Cyteir Therapeutics Inc disclose its ethnicity pay gap?
Does Cyteir Therapeutics Inc disclose cybersecurity risks?
Does Cyteir Therapeutics Inc use carbon offsets or credits exclusively for residual emissions (typically less than ~0.5–5% of total emissions)?
Does Cyteir Therapeutics Inc offer flexible work?
Does Cyteir Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Cyteir Therapeutics Inc disclose the number of employees in R&D functions?
Does Cyteir Therapeutics Inc plan to change its portfolio composition to lower the emissions intensity of its energy mix (e.g., by shifting from oil to gas, or by adding lower-carbon options like hydrogen, e-fuels, bioenergy, etc.)?
Does Cyteir Therapeutics Inc conduct supply chain audits?
Does Cyteir Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Cyteir Therapeutics Inc conduct 360 degree staff reviews?
Does Cyteir Therapeutics Inc disclose the individual responsible for D&I?
Does Cyteir Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Cyteir Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Cyteir Therapeutics Inc disclose water use targets?
Does Cyteir Therapeutics Inc have careers partnerships with academic institutions?
Did Cyteir Therapeutics Inc have a product recall in the last two years?
Does Cyteir Therapeutics Inc disclose incidents of discrimination?
Does Cyteir Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Cyteir Therapeutics Inc issued a profit warning in the past 24 months?
Does Cyteir Therapeutics Inc disclose parental leave metrics?
Does Cyteir Therapeutics Inc disclose climate scenario or pathway analysis?
Does Cyteir Therapeutics Inc disclose current and / or historical scope 1 emissions?
Does Cyteir Therapeutics Inc explicitly state that carbon offsets or credits are separate from its emissions-reduction progress or that they are not counted toward its emissions-reduction targets?
Are Operating Expesnses linked to emissions reduction?
Does Cyteir Therapeutics Inc disclose the pay ratio of women to men?
Does Cyteir Therapeutics Inc support suppliers with sustainability related research and development?
Does Cyteir Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Cyteir Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Cyteir Therapeutics Inc involved in embryonic stem cell research?
Does Cyteir Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Cyteir Therapeutics Inc disclose its waste policy?
Does Cyteir Therapeutics Inc report according to TCFD requirements?
Does Cyteir Therapeutics Inc plan to mitigate emissions from future new production assets through measures such as electrifying equipment, carbon capture and storage, repurposing waste gas, methane leak detection and repair, eliminating flaring, etc.?
Does Cyteir Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Cyteir Therapeutics Inc disclose energy use targets?
Does Cyteir Therapeutics Inc disclose its Renewable Energy targets?
Are emissions metrics verified by STBi?
Does Cyteir Therapeutics Inc have a policy relating to cyber security?
Potential Risks for Cyteir Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.